Advanced search
Start date

Evaluation of platelet activating factor receptor function in oral squamous carcinoma cells in vivo and in vitro

Grant number: 16/01884-8
Support type:Scholarships in Brazil - Doctorate
Effective date (Start): August 01, 2016
Effective date (End): September 30, 2018
Field of knowledge:Health Sciences - Dentistry
Principal Investigator:Andréia Machado Leopoldino
Grantee:Tálita Pollyanna Moreira dos Santos
Home Institution: Faculdade de Ciências Farmacêuticas de Ribeirão Preto (FCFRP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil


The oral squamous carcinoma cell (OSCC) is the most common neoplasia of the oral cavity. OSCC has a high rate of local invasiveness and to regional lymph nodes which contributes to poor prognosis. The understanding of their etiopathogenesis can contribute to a better targeting of pharmacological strategies and, consequently, improving the prognosis of this disease. The literature has emphasized the role of tumor microenvironment and their components which contributes for neoplastic progression. Among these, we highlight the role of G protein coupled receptors (GPCRs) which is included the platelet-activating factor receptor (PAFR) and its ligand. Its ligand is the lipid mediator platelet activating factor (PAF), which has pro-angiogenic and oncogenic properties already described in others epithelial neoplasias and, therefore, being established as a component which synergistically contribute to neoplastic progression. The hypothesis under study is that activation of the cell signaling pathway triggered from the PAF receptor contributes to a worse prognosis CCEB and pharmacological intervention with PAF receptor antagonist could soften this paper resulting in increased survival and decreased mortality resulting from oral cancer. As methodology we will use in vivo and in vitro studies involving animal models, human samples and OSCC cell line metastatic and non-metastatic. Is intended in the end of this project to have the determination of cell signaling pathway activated by PAF in oral carcinoma and characterization of the effects of PAFR receptor antagonist in neoplastic progression trying to establish a new biomarker to assist in the early diagnosis of the disease.